Results 261 to 270 of about 36,503 (286)

Synergistic seizure reduction in patient with persistently elevated N-desmethylclobazam levels, CYP450 genetic polymorphism, and responsive neurostimulator targeting centromedian nuclei of bilateral thalami. [PDF]

Epilepsy Behav Rep
Zillgitt A, Burdette DE, Yako A, Rashingkar R, Terrell A, Jacobs S, Staudt MD.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

CYP2C19 gene polymorphism in Ningxia

Pharmacological Reports, 2023
Poor metabolizer (PM) status of CYP2C19 can be a predisposing factor for developing gastric cancer in H. pylori-infected patients. It is unclear whether PM status of CYP2C19 can also be a potential factor for H.pylori infection in healthy people.We used high-throughput sequencing to detect single nucleotide polymorphisms (SNPs) at just three loci ...
Zhen Yang, Yunqian Xie, Daya Zhang, Yan Zou, Ximei Li, Runxiang Chen, Xiaodong Zhang, Shiju Chen, Feihu Bai   +8 more
openaire   +2 more sources

Identification of New Human CYP2C19 Alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian Poor Metabolizer of Mephenytoin

The Journal of Pharmacology and Experimental Therapeutics, 1998
A genetic polymorphism in the metabolism of the anticonvulsant drug S-mephenytoin has been attributed to defective CYP2C19 alleles. This genetic polymorphism displays large interracial differences with the poor metabolizer (PM) phenotype representing 2-5% of Caucasian and 13-23% of Oriental populations.
G C, Ibeanu, J A, Goldstein, U, Meyer, S, Benhamou, C, Bouchardy, P, Dayer, B I, Ghanayem, J, Blaisdell   +7 more
openaire   +2 more sources

Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study*

Clinical Pharmacology & Therapeutics, 1995
The reversible monoamine oxidase A inhibitor moclobemide was given in single (300 mg) and multiple doses (600 mg/day) to 11 male and four female healthy volunteers (age range, 23 to 27) who were either poor metabolizers of S-mephenytoin (n = 7) or extensive metabolizers of S-mephenytoin (n = 8). All were extensive metabolizers of sparteine.
Kirsten Vistisen, Kirsten Vistisen, Kirsten Vistisen, Lars F. Gram, Lars F. Gram, Lars F. Gram, Susan Grange, Susan Grange, Susan Grange, Kim Brøsen, Kim Brøsen, Kim Brøsen, Theodor W. Guentert, Theodor W. Guentert, Theodor W. Guentert   +14 more
openaire   +3 more sources

Assessment of CYP2C19 genetic polymorphisms in a korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles

Journal of Clinical Pharmacy and Therapeutics, 2010
CYP2C19 is a drug-metabolizing enzyme showing various genetic polymorphisms that may cause marked interindividual and interethnic variability in the disposition of its substrates. We assessed CYP2C19 genetic polymorphisms in a Korean population using a newly developed multiplex pyrosequencing method.A multiplex pyrosequencing method to simultaneously ...
Kim Kr, K.A. Kim, W K Song, Joori Park
openaire   +3 more sources

Clopidogrel, CYP2C19, and a Black Box

The Journal of Clinical Pharmacology, 2013
AbstractIt has been presumed that CYP2C19 has a major role in the metabolism of clopidogrel. This presumption has been based on in vitro drug metabolism studies using microsomes from baculovirus infected insect cells (BD‐Supersomes™). If clopidogrel were primarily a CYP2C19 substrate, a drug/drug interaction with CYP2C19 inhibitors, such as proton pump
Neville F. Ford, Dirk Taubert
openaire   +3 more sources

Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole

Molecular Biology Reports, 2011
To relate the pharmacokinetics of orally administered lansoprazole in healthy adult Jordanian men with CYP2C19 polymorphisms and to determine the percentage of CYP2C19 polymorphism in Jordanian population and the allelic frequency of CYP2C19*2 and CYP2C19*3.
Tawfiq Arafat, Nancy Hakooz, Nancy Hakooz, Imad Zalloum   +3 more
openaire   +3 more sources

Clopidogrel Inhibits CYP2C19‐Dependent Hydroxylation of Omeprazole Related to CYP2C19 Genetic Polymorphisms

The Journal of Clinical Pharmacology, 2009
This study explores the impact of clopidogrel on the pharmacokinetics of omeprazole related to CYP2C19 genetic polymorphisms. Twelve healthy volunteers (6 CYP2C19*1/*1, 5 CYP2C19*2/*2, and 1 CYP2C19*2/*3) are enrolled in a 2‐phase randomized crossover trial.
Yalin Li, Qian Li, Dan Wang, Bi-Lian Chen, Zhi-Rong Tan, Lian-Ci Wang, Lan Fan, Jiang-Hua Tu, Dong-Sheng Ouyang, Ye Chen, Hong Hao Zhou, Weidong Zhang, Dong-Li Hu   +12 more
openaire   +3 more sources

Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes

Xenobiotica, 2010
The objective of this study was to investigate the interaction between glycyrrhizin and omeprazole and observe the effects of glycyrrhizin on CYP2C19 and CYP3A4 activities in healthy Chinese male volunteers with different CYP2C19 genotypes. Eighteen healthy subjects (six CYP2C19*1/*1, five CYP2C19*1/*2, one CYP2C19*1/*3, five CYP2C19*2/*2 and one ...
L.-L. Dai, Zhi Li, Jiang-Hua Tu, Hong Hao Zhou, Y. Chen, Y. Sun, Dong-Li Hu, Zhi-Rong Tan, M. Zhang, Lan Fan   +9 more
openaire   +2 more sources

Functional characterization of two novel CYP2C19 variants (CYP2C19*18andCYP2C19*19) found in a Japanese population

Xenobiotica, 2007
Cytochrome P450 2C19 (CYP2C19) plays an important role in the metabolism of a wide range of therapeutic drugs and exhibits genetic polymorphism with interindividual differences in metabolic activity. We have previously described two CYP2C19 allelic variants, namely CYP2C19*18 and CYP2C19*19 with Arg329His/Ile331Val and Ser51Gly/Ile331Val substitutions,
N. Hanioka, N. Hanioka, Y. Tsuneto, Y. Saito, T. Sumada, K. Maekawa, K. Saito, J. Sawada, S. Narimatsu   +8 more
openaire   +2 more sources